// App-Quantinova.ai

: Impact of urinary and late-night salivary cortisol levels on clinical signs of hypercortisolism and quality of life in patients with Cushing’s disease treated with osilodrostat

Researchers

Presenter

  • John Newell-Price

Principal Investigators

  • Maria Fleseriu

  • Rosario Pivonello

  • Richard Feelders

  • Andre Lacroix

  • Richard Auchus

  • Andrea Piacentini

  • Alberto Pedroncelli

  • Beverly M.K. Biller

Medical Centers

  • The Medical School, University of Sheffield, Department of Oncology and Metabolism, Sheffield, United Kingdom

  • Oregon Health & Science University, Pituitary Center, Departments of Medicine and Neurological Surgery, Portland, OR, United States

  • Erasmus University Medical Center, Internal Medicine, Division of Endocrinology, Rotterdam, Netherlands

  • Centre Hospitalier de LUniversite de Montreal (CHUM), Montreal, QC, Canada

  • University of Michigan, Ann Arbor, Division of Metabolism, Endocrinology and Diabetes, Ann Arbor, MI, United States

  • Recordati SpA, Milan, Italy

  • Recordati AG, Basel, Switzerland

  • Massachusetts General Hospital, Neuroendocrine and Pituitary Tumor Clinical Center, Boston, MA, United States

Locations

  • United Kingdom

  • United States

  • Italy

  • Netherlands

  • Canada

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

  • Endocrine/metabolic Diseases (ME)

Disease

  • Cushing's syndrome

  • Depression

Biomarkers

  • Cortisol

Drug/Treatment

  • LCI699

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Open Label

  • Controlled

Phase

  • III

Study Id's

  • NCT02180217

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved